- Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments
- ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE
- ENZO BIOCHEM REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 RESULTS AND PROVIDES BUSINESS UPDATE
- Steven J. Pully Appointed to Enzo Biochem’s Board of Directors
- Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO
- Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.04 |
---|---|
High | 1.09 |
Low | 1.04 |
Bid | 1.04 |
Offer | 1.28 |
Previous close | 1.06 |
Average volume | 120.85k |
---|---|
Shares outstanding | 51.23m |
Free float | 38.83m |
P/E (TTM) | -- |
Market cap | 54.30m USD |
EPS (TTM) | -0.4699 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 00:00 BST.
More ▼